NTRA News and Press, Natera Inc. From 08/18/20

SAN CARLOS, Calif. , Aug. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) , a leader in non-invasive prenatal testing, announced a joint guideline released yesterday by the American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM), regarding ...

Natera ( NTRA -1.0% ) has filed an additional suit against ArcherDX for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"), alleging that ArcherDX's sale and use of certain cell-free DNA-based oncology products infringes on the '220 Patent. More news...

SAN CARLOS, Calif. , Aug. 7, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"). The complaint was filed in...

FinancialBuzz.com News Commentary New York, NY (8/6/2020) – The diagnostics industry is highly diverse, with a vast number of testing methods already on the market and a consistent flow of new technologies. In fact, diagnostics are no longer just about the detection of diseases, and now...

Natera, Inc. (NTRA) Q2 2020 Earnings Conference Call August 05, 2020, 04:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Bob Schueren - Chief Operating Officer Solomon Moshkevich - General Manager, Oncology and Tran...

Natera (NASDAQ: NTRA ) : Q2 GAAP EPS of -$0.75 misses by $0.16 . More news on: Natera, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN CARLOS, Calif. , Aug. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. Recen...

SAN CARLOS, Calif. , Aug. 3, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a manuscript in Nature Cancer 1 that validates the ability of its Signatera™ personalized circulati...

Natera (NTRA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook gives a good sense of the company’s earnings picture, but how the actual results compare to thes...

FinancialBuzz.com News Commentary New York, NY (7/29/2020) – The diagnostics industry is a large and diverse entity, with new innovative technology constantly under development. Diagnostic tests are usually conducted in laboratories, private or public, which are equipped with appropriat...